Zepbound News & Analysis
2 articles
Market Mood
Eli Lilly (LLY) Sees 700,000 Seniors Start GLP-1 Treatments
Eli Lilly CEO Dave Ricks reported that since the launch of Medicare coverage for obesity drugs in July, 700,000 new seniors have begun GLP-1 treatments, with 70% opting for Lilly medications. The coverage allows eligible seniors to access weight loss drugs for a $50 monthly co-pay. Lilly's Zepbound and Foundayo are noted as leading choices among patients, with one-third of new oral GLP-1 patients using Foundayo. The increase in patients shows significant market expansion for obesity treatments, which potentially benefits Eli Lilly (LLY) significantly.
Read More: Eli Lilly (LLY) Sees 700,000 Seniors Start GLP-1 Treatments
Lilly's Taltz and Zepbound Show Efficacy in Psoriatic Arthritis Trial Results
Eli Lilly reported positive outcomes from clinical trials for its psoriatic arthritis treatments, Taltz and Zepbound. The trial demonstrated significant efficacy, leading to a potential increase in demand for these treatments. Clinical trials are crucial as they assess the potential market for pharmaceuticals, impacting sales forecasts. Continuing developments in this area can influence investor sentiment and stock valuation.
Read More: Lilly's Taltz and Zepbound Show Efficacy in Psoriatic Arthritis Trial Results